These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 9276200

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Familial juvenile parkinsonism.
    Yokochi M.
    Eur Neurol; 1997; 38 Suppl 1():29-33. PubMed ID: 9276198
    [Abstract] [Full Text] [Related]

  • 4. Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family.
    Wider C, Skipper L, Solida A, Brown L, Farrer M, Dickson D, Wszolek ZK, Vingerhoets FJ.
    Parkinsonism Relat Disord; 2008 Aug; 14(6):465-70. PubMed ID: 18342564
    [Abstract] [Full Text] [Related]

  • 5. Genetic linkage studies in autosomal dominantly inherited L-DOPA responsive parkinsonism. Evaluation of candidate genes.
    Gasser T, Wszolek Z, Supala A, Trofatter J, Ozelius L, Uitti RJ, Pfeiffer RF, Gusella J, Calne D, Breakefield XO.
    Adv Neurol; 1996 Aug; 69():87-95. PubMed ID: 8615189
    [No Abstract] [Full Text] [Related]

  • 6. Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions.
    Socal MP, Emmel VE, Rieder CR, Hilbig A, Saraiva-Pereira ML, Jardim LB.
    Parkinsonism Relat Disord; 2009 Jun; 15(5):374-8. PubMed ID: 18990604
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Levodopa response in dementia with lewy bodies: a 1-year follow-up study.
    Lucetti C, Logi C, Del Dotto P, Berti C, Ceravolo R, Baldacci F, Dolciotti C, Gambaccini G, Rossi G, Bonuccelli U.
    Parkinsonism Relat Disord; 2010 Sep; 16(8):522-6. PubMed ID: 20615745
    [Abstract] [Full Text] [Related]

  • 9. A family with hereditary juvenile dystonia-parkinsonism.
    Ishikawa A, Miyatake T.
    Mov Disord; 1995 Jul; 10(4):482-8. PubMed ID: 7565830
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Dopa-therapy in the treatment of early stage Parkinson's disease].
    Broussolle E.
    Rev Neurol (Paris); 2000 Jul; 156 Suppl 2 Pt 2():91-7. PubMed ID: 10916042
    [No Abstract] [Full Text] [Related]

  • 15. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease.
    Infante J, Rodríguez E, Combarros O, Mateo I, Fontalba A, Pascual J, Oterino A, Polo JM, Leno C, Berciano J.
    Neurosci Lett; 2006 Mar 13; 395(3):224-6. PubMed ID: 16298482
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S, Parkinson Study Group.
    J Neurol; 2005 Oct 13; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J, US01 Study Team.
    Arch Neurol; 2004 Oct 13; 61(10):1563-8. PubMed ID: 15477510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.